Behavioral Health Feasibility Study: What to Validate Before Committing Capital to a New Clinic

Behavioral health demand can be substantial and a specific clinic can still be a poor investment.

That distinction is easy to miss.

Community prevalence, long wait times, provider shortages, or a mission-driven case for expanding access may establish that more care is needed. They do not automatically establish that a particular service mix, location, payer strategy, staffing model, and cost structure can operate sustainably.

For a founder, board, investor, or executive team, the feasibility question is therefore narrower and more demanding: can this proposed clinic convert a real need into an accessible, reimbursable, operationally deliverable service model?

John Lynch & Associates treats a market and feasibility study as an evidence problem rather than a confidence exercise. The purpose is not to collect enough positive facts to justify a decision leadership already wants to make. The purpose is to identify the assumptions that must be true, test them with the best available evidence, and make the unresolved risks visible before more capital is committed.

That is especially important in behavioral health, where the same concept can produce very different results depending on level of care, population served, licensure, referral patterns, payer participation, clinical staffing, supervision, scheduling, documentation requirements, facility design, and technology.

A feasibility study becomes unreliable when the proposed clinic is described too broadly. “Behavioral health clinic” is not a sufficient operating model.

Leadership should be able to define, at a practical level, who the clinic intends to serve, which services will be available at launch, how care will be delivered, how frequently patients are expected to use those services, what hours the clinic will operate, which roles are required, and which payer segments are expected to fund the work.

Those choices affect almost every downstream assumption. An outpatient therapy model, medication-management practice, intensive outpatient program, substance use treatment service, or mixed model can create different referral pathways, staffing requirements, facility needs, documentation workflows, payer rules, and technology requirements. The feasibility study should therefore start with the service model and let the market analysis test that model, not the other way around.

This is also where an early regulatory screen matters. In Arizona, the applicable Arizona Department of Health Services Bureau of Behavioral Health Facilities Licensing path depends on the facility and services being proposed, and the Department now routes applications and renewals through its Licensing Management System.

Licensing should not be treated as a late administrative task after a site has been selected. If the service model changes the facility, staffing, or operating requirements, it can change the investment case itself.

The most common feasibility shortcut is to move from “people need this service” to “our clinic will have enough patients.” Those are different claims.

Population and prevalence data can help establish the size and characteristics of a community. Treatment directories and competitor mapping can show where services are currently offered. Referral interviews can reveal whether hospitals, primary care practices, schools, community organizations, payers, or other behavioral health providers are encountering access gaps. Existing organizations can review internal referral leakage, wait lists, denied referrals, and service-line demand.

No single source should carry the conclusion. SAMHSA’s FindTreatment.gov can help identify mental health and substance use treatment facilities by geography and service characteristics, but it is still a starting point for local validation. A directory may show that a provider exists without proving current capacity, appointment availability, referral acceptance, or fit for the population the proposed clinic intends to serve.

The leadership question is more operational: where will patients actually come from, what prevents them from using the proposed service today, and what evidence suggests those barriers can be overcome by this clinic?

A strong demand case should become specific enough to test. If the model depends on five major referral sources, leadership should know whether those sources generate the relevant patient population, whether referral pathways are realistic, and whether the clinic’s hours, location, language capability, telehealth model, or intake process match how those patients can access care.

Need becomes commercially meaningful only when there is a plausible path from population to referral, from referral to completed intake, and from intake to an appropriate billable service.

Even a credible patient-volume forecast can overstate feasibility if the payer assumptions are weak.

Leadership should distinguish the payer mix it hopes to serve from the payers and plans it can realistically enroll with, contract with, credential for, and bill under the proposed service model. That requires more than listing Medicare, Medicaid, commercial insurance, and self-pay as percentages in a spreadsheet.

For Arizona organizations, AHCCCS publishes county-level enrollment by health plan and maintains an online provider directory that is updated daily. Those sources can help leaders understand Medicaid market context and the existing provider landscape.

They do not eliminate the need for plan-specific network and contracting work. AHCCCS explicitly notes that an enrolled provider may or may not be contracted with every AHCCCS managed care organization.

That distinction should influence the feasibility model before revenue is forecast. If a large share of projected volume depends on one or two plans, leadership needs evidence about network participation, applicable provider enrollment, credentialing, covered services, authorization requirements, and the operational steps required to submit compliant claims.

This is where feasibility and behavioral health billing readiness intersect. Revenue does not begin with a reimbursement rate. It begins with an operating pathway that can consistently convert an eligible patient, authorized service when required, complete documentation, and accurate claim into collectible revenue.

A forecast that assumes full reimbursement without modeling those dependencies is not conservative. It is incomplete.

A clinic can have real demand and favorable payer opportunity but still be infeasible because the delivery model cannot be staffed, licensed, housed, or operated at the expected cost and productivity.

Staffing is often the most visible constraint, but it should be tested as a system. Leadership needs to understand:

• which roles are required,
• which positions drive clinical capacity,
• how supervision affects throughput,
• how vacancies would constrain service volume,
• whether recruiting assumptions are realistic for the location and schedule.

A staffing plan that works only at full hiring is different from one that can operate safely and financially through vacancies or slower recruiting.

Facility choices also need to follow the service model. A lower-cost site is not necessarily a better site if it limits accessibility, creates workflow friction, cannot support the intended patient flow, or requires changes that were not included in the original capital estimate.

Conversely, a premium location may not improve feasibility if referral patterns and payer access do not support the additional fixed cost.

Technology should be evaluated the same way. Behavioral health EHR workflows, intake, scheduling, authorization tracking, documentation, billing, telehealth, reporting, and privacy requirements need to support the proposed model without creating an expensive layer of manual work. The question is not whether an EHR can be purchased. It is whether the operating model can be translated into workable system configuration and staff routines.

For an existing organization considering another location or service line, the same discipline applies. Demand for expansion does not necessarily mean the current operating model is ready to scale.

If the existing organization relies on informal handoffs, workarounds, inconsistent reporting, or a small number of key employees, expansion can reproduce those weaknesses at a larger cost.

A useful feasibility study should change how capital decisions are sequenced.

Instead of treating the project as a single yes-or-no decision, leadership can define the evidence that must exist before the next irreversible commitment. That creates a practical series of gates.

The point is not to eliminate uncertainty. No feasibility study can predict patient volume, payer decisions, staffing markets, or launch conditions with certainty.

The goal is to make uncertainty explicit and decision-relevant. Leadership should know which assumptions are well supported, which are directional, which remain untested, and which would materially change the decision if they prove wrong.

This is also where a feasibility study should be willing to recommend a different answer than “proceed.” A viable conclusion may be to narrow the initial service mix, choose a different location, delay a capital commitment, secure a payer pathway first, change the staffing model, or redesign the clinic before investing further.

A feasibility process that can only confirm the original concept is not doing enough work.